Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 17 results found. Search for [ adverse events during vaccination ]

Results 1 to 17 of 17
BusinessToday.In
March 1, 2021
Stock Market Updates Today: Sectorally, all the indices were rising, with 1.8% rise in media, financial services, PSU Bank and private banking indices.


PTI
February 21, 2021
On Saturday, coronavirus vaccine shots were administered to over 26,000 beneficiaries in Delhi, the inoculation figures crossing the 24,000-mark for the third consecutive day


Reuters
February 19, 2021
Symptoms, as reported in clinical trials for the AstraZeneca shot, can include a high temperature or headache and are a normal sign that the body is generating an immune response


Rashi Bisaria
New Delhi, January 18, 2021
COVID-19 vaccination Day 2: 2.25 lakh inoculated; 447 adverse events reported A total of 2,24,301 beneficiaries have been inoculated with COVID-19 vaccine so far, out of which only 447 adverse events following immunisation (AEFI) were reported, the Union Health Ministry said on day two of the nationwide vaccination drive on Sunday. Out of the 447 adverse events following immunisation, only three required hospitalisation. India has approved two vaccines -- Covaxin developed by Bharat Biotech...


BusinessToday.In
January 16, 2021
Coronavirus vaccination drive: Covaxin has asked its recipients to sign a consent form. The form also states that in case of adverse effects, the recipient would be compensated


BusinessToday.In
January 16, 2021
In the consent form for getting Covaxin vaccine, recipients have been promised that in case of any adverse situation following the administration of the vaccine and if it is determined that the vaccine was the cause then the recipients will be given compensation and medical


PTI
January 14, 2021
Vaccination will be held at 311 places in all the 75 districts of the state on January 16. The drive will start at 9 am and will continue till 5 pm, said Additional Chief Secretary of Health Amit Mohan Prasad


BusinessToday.In
January 14, 2021
Company shall be liable for all adversities as per CDSCO/Drugs and Cosmetics Act/DCGI policy/approval, says government's purchase order with vaccine makers


BusinessToday.In
January 9, 2021
Bharat Biotech revealed that one of the participants for Phase III trials passed away on December 21, 2020, and the death was reported to the People's College of Medical Sciences and Research Centre by the son of the deceased


BusinessToday.In
January 2, 2021
The SEC has recommended Covaxin for emergency use authorisation; the recommendation, along with rollout modalities, will now be taken up by the DCGI for a final decision on the matter


BusinessToday.In
December 25, 2020
Around 2,360 participants have been trained during the national-level training. The state-level training has been completed in all states/UTs and 7,000 district level trainees got hands-on experience on vaccine handling and distribution


BusinessToday.In
December 16, 2020
Coronavirus vaccine: Health Secretary Rajesh Bhushan also said that the ministry has prepared training modules for vaccinators, cold chain handlers and ASHA (Accredited Social Health Activist) coordinators


BusinessToday.In
December 1, 2020
Balram Bhargava, Director General of Indian Council of Medical Research (ICMR), said that the primary objective of vaccination is to break the COVID-19 transmission chain


BusinessToday.In
October 9, 2020
Bharat Biotech vaccine: The subject expert committee that discussed the matter in a meeting on October 5 has asked the company to resubmit the protocol and clarify the definition of asymptomatic


BusinessToday.In
September 16, 2020
Besides, the drug regulating body of the country has told the Serum Institute to take extra care during screening, provide additional information in informed consent, and closely monitor participants for any adverse events during follow-up of the study


BusinessToday.In
September 12, 2020
\"Once DCGI (Drugs Controller General of India) gives us permission to restart the trials in India, we will resume the trials,\" SII CEO Adar Poonawalla said on Saturday


BusinessToday.In
September 12, 2020
Bharat Biotech says its vaccine candidate was found to generate \"robust immune responses\", thus preventing infection and disease in primates upon high amounts of exposure to live SARS-CoV-2 virus


PAGES 1 OF 1